Antibacterial agents used in COVID-19: A systematic review and meta-analysis

Abd-Elsalam S, Esmail ES, Khalaf M, Abdo EF, Medhat MA, Abd El Ghafar MS, Ahmed OA, Soliman S et al (2020) Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. Am J Trop Med Hyg 103:1635–1639 An MH, Kim MS, Kim BO, Kang SH, Kimn WJ, Park SK, Park HW, Yang W et al (2020) Treatment response to hydroxychloroquine and antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea. medRxiv. https://doi.org/10.1101/2020.07.04.20146548 Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, Bhimani Z, Bonten M et al (2020) The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study. Rationale and design. Ann Am Thorac Soc 17:879–891 Banerjee T, Anupurba S, Singh DK (2013) Poor compliance with the antibiotic policy in the intensive care unit (ICU) of a tertiary care hospital in India. J Infect Dev Ctries 15:7 Banerjee T, Mishra A, Das A, Sharma S, Barman H, Yadav G (2018) High prevalence and endemicity of multidrug resistant Acinetobacter spp. in intensive care unit of a Tertiary Care Hospital, Varanasi, India. J Pathog 2018:9129083 Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourão MPG, Brito-Sousa JD et al (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 3:e208857 Buetti N, Mazzuchelli T, Priore EL, Balmelli C, Llamas M, Pallanza M, Elzi L, Consonni V et al (2020) Early administered antibiotics do not impact mortality in critically ill patients with COVID-19. J Infect 81:e148–e149 Calderón JM, Flores MD, Coria LP, Garduño JC, Figueroa JM, Contretas MJ, De la Cruz ÁL, Meza SD et al (2020) Nitazoxanide against COVID-19 in three explorative scenarios. J Infect Dev Ctries 14:982–986 Caselli E (2020) Hygiene: microbial strategies to reduce pathogens and drug resistance in clinical settings. Microb Biotechnol 10:1079–1083 Chen J, Bai H, Liu J, Chen G, Liao Q, Yang J, Wu P, Wei J et al (2020) Distinct clinical characteristics and risk factors for mortality in female COVID-19 inpatients: a sex-stratified large-scale cohort study in Wuhan, China. Clin Infect Dis 8:ciaa920 National Institute for Health and Care Excellence (NICE) (2020) COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital [Internet]. https://www.nice.org.uk/guidance/ng173. Accessed 1 Oct 2020 Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, Kazemzadeh H, Yekaninejad MS (2020) A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother 64:e01061-e1120 de Melo AC, Thuler LC, da Silva JL, de Albuquerque LZ, Pecego AC, Rodrigues LD, da Conceicao MS, Garrido MM et al (2020) Cancer inpatients with COVID-19: a report from the Brazilian National Cancer Institute. PLoS One 15:e0241261 Durojaiye AB, Clarke JR, Stamatiades GA, Wang C (2020) Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies. J Biomol Struct Dyn 13:1–8 Editorial (2020) Antimicrobial resistance in the age of COVID-19 Nat Microbiol 5:779 Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D et al (2020) A Multicenter Study of Clinical Features. Am J Respir Crit Care Med 201:1380–1388 Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, Zampieri FG, Veiga VC et al (2020) Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet 396:959–967 Gagliotti C, Buttazzi R, Ricchizzi E, Di Mario S, Tedeschi S, Moro ML (2020) Community use of antibiotics during the COVID-19 lockdown. Infect Dis (lond) 19:1–3 Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56:105949 Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH (2020) Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ 98:442-442A Glasziou PP, Sanders SL (2002) Investigating causes of heterogeneity in systematic reviews. Stat Med 21:1503–1511 Hariri G, Tankovic J, Boëlle PY, Dubée V, Leblanc G, Pichereau C, Bourcier S, Bigé N et al (2017) Are third-generation cephalosporins unavoidable for empirical therapy of community-acquired pneumonia in adult patients who require ICU admission? A retrospective study. Ann Intensive Care 7:35 Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane handbook for systematic reviews of interventions, 2nd edn. Wiley, Chichester Hu W, Lv X, Li C, Xu Y, Qi Y, Zhang Z, Li M, Cai F et al (2020) Disorders of sodium balance and its clinical implications in COVID-19 patients: a multicenter retrospective study. Intern Emerg Med 16:1–10 Huang Q, Deng X, Li Y, Sun X, Chen Q, Xie M, Liu S, Qu H, Liu S, Wang L, He G (2020) Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China. Int J Clin Pharm 42:837–845 Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J et al (2020) Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395:1695–1704 Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J (2020) COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect 26:808–810 Ji M, Yuan L, Shen W, Lv J, Li Y, Li M, Lu X, Hu L et al (2020) Characteristics of disease progress in patients with coronavirus disease 2019 in Wuhan. China. Epidemiol Infect 148:e94 Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, Hao SR, Jia HY et al (2020) Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 69:1002–1009 Karami Z, Knoop BT, Dofferhoff ASM, Blaauw MJT, Janssen NA, van Apeldoorn M, Kerckhoffs APM, van de Maat JS (2020) Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (lond) 24:1–9 Khamis F, Al-Zakwani I, Al Naamani H, Al Lawati S, Pandak N, Omar MB, Al Bahrani M, Bulushi ZA et al (2020) Clinical Characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: an experience from Oman. J Infect Public Health 13:906–913 Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR, Daneman N (2020) Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 22 Lehmann CJ, Pho MT, Pitrak D, Ridgway JP, Pettit NN (2020) Community acquired co-infection in COVID-19: a retrospective observational experience. Clin Infect Dis 1:ciaa902 Lian J, Jin X, Hao S, Jia H, Cai H, Zhang X, Hu J, Zheng L et al (2020) Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China. Influenza Other Respir Viruses 14:564–574 Mancilla-Galindo J, Garcia-Mendez JO, Marquez-Sanchez J, Reyes-Casarrubias RE, Aguirre-Aguilar E, Rocha-Gonzalez HI, Kammar-Garcia A (2020) Use of antivirals and antibiotics for COVID-19 in Mexico City: a real-world Multicenter Cohort Study. medRxiv. https://doi.org/10.1101/2020.10.13.20211797 Mason CY, Kanitkar T, Richardson CJ, Lanzman M, Stone Z, Mahungu T, Mack D, Wey EQ et al (2020) Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. medRxiv. https://doi.org/10.1101/2020.10.09.20199778 Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A et al (2020) Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 136:1134–1143 Moher D, Liberati J, Tetzlaff DG, Altman P, Grp (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (reprinted from Annals of Internal Medicine). Phys Ther 89:873–880 Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Fulviis S, Nardiello I, Beretta A et al (2020) Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care 58:29–33 Prata-Barbosa A, Lima-Setta F, Santos GRD, Lanziotti VS, de Castro REV, de Souza DC, Raymundo CE, de Oliveira et al (2020) Pediatric patients with COVID-19 admitted to intensive care units in Brazil: a prospective multicenter study. J Pediatr (Rio J) 96:582–592 Rossato L, Negrão FJ, Simionatto S (2020) Could the COVID-19 pandemic aggravate antimicrobial resistance? Am J Infect Control 48:1129–1130 Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, Hosamirudsai H, Afhami S et al (2020) Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother 75:3379–3385 Santoro F, Monitillo F, Raimondo P, Lopizzo A, Brindicci G, Gilio M, Musaico F, Mazzola M et al (2020) QTc interval prolongation and life-threatening arrhythmias during hospitalization in patients with COVID-19. Results from a multi-center prospective registry. Clin Infect Dis 24:ciaa1578 Seaton RA, Gibbons CL, Cooper L, Malcolm W, McKinney R, Dundas S, Griffith D, Jeffreys D et al (2020) Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect 26:952–960 Sekhavati E, Jafari F, SeyedAlinaghi S, Jamalimoghadamsiahkali S, Sadr S, Tabarestani M, Pirhayati M, Zendehdel A et al (2020) Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. Int J Antimicrob Agents 56:106143 Spinner CD, Gottlieb RL, Criner GJ, López JR, Cattelan AM, Viladomiu AS, Ogbuagu O, Malhotra P et al (2020) Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324:1048–1057 Staub MB, Beaulieu RM, Graves J, Nelson GE (2020) Changes in antimicrobial utilization during the COVID-19 pandemic after implementation of a multispecialty clinical guidance team. Infect Control Hosp Epidemiol 26:1–28 Stevens RW, Jensen K, O’Horo JC, Shah A (2020) Antimicrobial prescribing practices at a tertiary-care center in patients diagnosed with COVID-19 across the continuum of care. Infect Control Hosp Epidemiol 24:1–4 Strathdee SA, Davies SC, Marcelin JR (2020) Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. Lancet 396:1050–1053 Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G (2020) Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug Saf 43:691–698 Sun L, Shen L, Fan J, Gu F, Hu M, An Y, Zhou Q, Fan H et al (2020) Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China. J Med Virol 92:2055–2066 Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W et al (2020) Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 369:1849 Tawfik GM, Dila KA, Mohamed MY, Tam DN, Kien ND, Ahmed AM, Huy NT (2019) A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health 47:46 Tian R, Wu W, Wang C, Pang H, Zhang Z, Xu H, Luo Q, Gao P et al (2020) Clinical characteristics and survival analysis in critical and non-critical patients with COVID-19 in Wuhan, China: a single-center retrospective case control study. Sci Rep 10:17524 Wei W, Ortwine JK, Mang NS, Joseph C, Hall BC, Prokesch BC (2020) Limited role for antibiotics in COVID-19: scarce evidence of bacterial coinfection (SSRN 3622388) Williams EJ, Mair L, de Silva TI, Green DJ, House P, Cawthron K, Gillies C, Wigfull J et al (2020) Routine measurement of serum procalcitonin allows antibiotics to be safely withheld in patients admitted to hospital with SARS-CoV-2 infection. medRxiv. https://doi.org/10.1101/2020.06.29.20136572 World Health Organization (2020) Clinical management of COVID-19: interim guidance. World Health Organization Yang Q, Xie L, Zhang W, Zhao L, Wu H, Jiang J, Zou J, Liu J et al (2020) Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019. J Clin Pharm Ther 45:609–616 Yin X, Liu L, Xu X, Huang L, Jing P, Li H, Jiang N, Wang J et al (2020) Evaluation of early antibiotics use in non-severe COVID-19 patients admitted with low risk of bacterial infection. medRxiv. https://doi.org/10.21203/rs.3.rs-39522/v1 Yu B, Li C, Chen P, Zhou N, Wang L, Li J, Jiang H, Wang DW (2020) Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci 15:1–7